Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/107753
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Darbà, Josep | - |
dc.contributor.author | Ramírez, Gabriela | - |
dc.contributor.author | García-Rivero, Juan L. | - |
dc.contributor.author | Mayoralas, Sagrario | - |
dc.contributor.author | Pascual, José Francisco | - |
dc.contributor.author | Roger, Albert | - |
dc.contributor.author | Vargas, Diego | - |
dc.contributor.author | Bijedic, Adi | - |
dc.date.accessioned | 2017-03-02T15:37:24Z | - |
dc.date.available | 2017-03-02T15:37:24Z | - |
dc.date.issued | 2016-09 | - |
dc.identifier.issn | 1178-6981 | - |
dc.identifier.uri | http://hdl.handle.net/2445/107753 | - |
dc.description.abstract | To assess the economic impact of the introduction of DuoResp(®) Spiromax(®) by focusing on a potential improvement in the inhalation technique to strengthen medication adherence for the treatment of moderate to severe asthmatics in Spain and five Spanish regions including Andalusia, Catalonia, Galicia, Madrid, and Valencia. ... | - |
dc.format.extent | 10 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Dove Medical Press | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.2147/CEOR.S111453 | - |
dc.relation.ispartof | Clinicoeconomics and Outcomes Research, 2016, vol. 8 , p. 435-444 | - |
dc.relation.uri | https://doi.org/10.2147/CEOR.S111453 | - |
dc.rights | cc-by-nc (c) Darbà, Josep et al., 2016 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es | - |
dc.source | Articles publicats en revistes (Economia) | - |
dc.subject.classification | Administració de medicaments | - |
dc.subject.classification | Asma | - |
dc.subject.classification | Malalties pulmonars obstructives cròniques | - |
dc.subject.classification | Tractament tèrmic | - |
dc.subject.classification | Economia de la salut | - |
dc.subject.other | Administration of drugs | - |
dc.subject.other | Asthma | - |
dc.subject.other | Chronic obstructive pulmonary diseases | - |
dc.subject.other | Heat treatment | - |
dc.subject.other | Medical economics | - |
dc.title | A budget impact analysis of Spiromax compared with Turbuhaler for the treatment of moderate to severe asthma: a potential improvement in the inhalation technique to strengthen medication adherence could represent savings for the Spanish Healthcare System and five Spanish regions | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 668397 | - |
dc.date.updated | 2017-03-02T15:37:24Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 27660476 | - |
Appears in Collections: | Articles publicats en revistes (Economia) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
668397.pdf | 270.56 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License